Stay updated with breaking news from Drug Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy infants1,2Nirsevimab is the first investigational immunization designed to protect all infants across th...
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1 5 Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season. Nirsevimab met its Phase 3 primary endpoint earlier than anticipated; regulatory submissions for all-infant indication to begin in 2022. PARIS – April 26, 2021 – Positive topline results from the Phase 3 MELODY...
Last Updated: Iraq Approves Sinopharm, AstraZeneca COVID-19 Vaccines For Emergency Use Against COVID-19 Iraq authorities approve the coronavirus vaccines by UK-Swedish company AstraZeneca and China's Sinopharm for emergency use On Tuesday, January 19, Iraqi authorities approved the emergency use of coronavirus vaccines by UK-Swedish company AstraZeneca and China's Sinopharm. In a statement, the Iraqi Ministry of Health said, “The National Authority for Drug Selection has approved vaccines by the UK's AstraZeneca and China's Sinopharm for emergency use to fight the coronavirus pandemic....